NANoREG D5 07

NANoREG D6 03 DR Comparison on toxicity testing in drug development and in present MNMs safety testing

Acesse:

https://www.rivm.nl/en/documenten/nanoreg-d6-03-dr-comparison-on-toxicity-testing-in-drug-development-and-in-present-mnms

NANoREG D4 05 DR Lung burden and particle detection and quantification in olfactory bulbs chronic exposure

Acesse:

https://www.rivm.nl/en/documenten/nanoreg-d4-05-dr-lung-burden-and-particle-detection-and-quantification-in-olfactory 

NANoREG D3 05 DR Development of an aquatic Mesocosms Platform

Acesse:

https://www.rivm.nl/en/documenten/nanoreg-d3-05-dr-development-of-aquatic-mesocosms-platform 

NANoREG D6.05 Database sql

Acesse:

https://www.rivm.nl/en/documenten/nanoreg-d605-database-sql 

NANoREG D5 06 DR Identification and optimization of the most suitable in vitro methodology

Acesse:

https://www.rivm.nl/en/documenten/nanoreg-d5-06-dr-identification-and-optimization-of-most-suitable-in-vitro-methodology 

SOPs available in deliverable:

• SOP 01 LAL Assay for Nanoparticles
• SOP 02 LDH assay
• SOP 03 Reaction Oxygen Species Detection
• SOP 04 Human Lung Cell transformation assay. Long term chronic experiment
• SOP 05 Apoptosis/Necrosis Analysis
• SOP 06 Production of pro-inflammatory cytokines

NANoREG D5.07 SOP 19 Whole blood cell assay for cytokine production

Acesse:

https://www.rivm.nl/documenten/nanoreg-d507-sop-19-whole-blood-cell-assay-for-cytokine-production